MX2022008875A - Inhibidores terapeuticos de tirosina quinasa para esclerosis multiple recidivante (emr). - Google Patents

Inhibidores terapeuticos de tirosina quinasa para esclerosis multiple recidivante (emr).

Info

Publication number
MX2022008875A
MX2022008875A MX2022008875A MX2022008875A MX2022008875A MX 2022008875 A MX2022008875 A MX 2022008875A MX 2022008875 A MX2022008875 A MX 2022008875A MX 2022008875 A MX2022008875 A MX 2022008875A MX 2022008875 A MX2022008875 A MX 2022008875A
Authority
MX
Mexico
Prior art keywords
tyrosine kinase
therapeutic
multiple sclerosis
rms
kinase inhibitors
Prior art date
Application number
MX2022008875A
Other languages
English (en)
Inventor
Erik Wallstroem
Meehyung Cho
Timothy J Turner
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of MX2022008875A publication Critical patent/MX2022008875A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente descripción se refiere al campo de los inhibidores terapéuticos de tirosina quinasa, en particular a los inhibidores de la tirosina quinasa de Bruton ("BTK") para el tratamiento de sujetos con esclerosis múltiple recidivante.
MX2022008875A 2020-01-20 2021-01-19 Inhibidores terapeuticos de tirosina quinasa para esclerosis multiple recidivante (emr). MX2022008875A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202062963238P 2020-01-20 2020-01-20
US202062970502P 2020-02-05 2020-02-05
US202063013895P 2020-04-22 2020-04-22
PCT/US2021/013883 WO2021150476A1 (en) 2020-01-20 2021-01-19 Therapeutic tyrosine kinase inhibitors for relapsing multiple sclerosis (rms)

Publications (1)

Publication Number Publication Date
MX2022008875A true MX2022008875A (es) 2022-08-11

Family

ID=74626161

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022008875A MX2022008875A (es) 2020-01-20 2021-01-19 Inhibidores terapeuticos de tirosina quinasa para esclerosis multiple recidivante (emr).

Country Status (12)

Country Link
US (1) US11969418B2 (es)
EP (1) EP4093397A1 (es)
JP (1) JP2023510604A (es)
KR (1) KR20220130179A (es)
CN (1) CN115348862A (es)
AU (1) AU2021209608A1 (es)
BR (1) BR112022014058A2 (es)
CA (1) CA3168146A1 (es)
IL (1) IL294560A (es)
MX (1) MX2022008875A (es)
TW (1) TW202140002A (es)
WO (1) WO2021150476A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115348862A (zh) 2020-01-20 2022-11-15 建新公司 用于复发型多发性硬化症(rms)的治疗性酪氨酸激酶抑制剂
AU2021398051A1 (en) * 2020-12-10 2023-07-27 Genzyme Corporation Crystal form of tolebrutinib, preparation method therefor and use thereof
EP4328226A1 (en) * 2021-04-23 2024-02-28 Hangzhou Solipharma Co., Ltd. Tolebrutinib crystal form, amorphous form, preparation method therefor and use thereof
CN117412749A (zh) * 2021-05-21 2024-01-16 杭州领业医药科技有限公司 Tolebrutinib盐及其晶型、其制备方法、其药物组合物和用途
EP4353723A1 (en) * 2021-06-11 2024-04-17 Genzyme Corporation Crystal form of tolebrutinib, preparation method therefor and use thereof
WO2023280132A1 (zh) * 2021-07-06 2023-01-12 苏州晶云药物科技股份有限公司 氧代二氢咪唑并吡啶类化合物的晶型及其制备方法
WO2024006406A1 (en) * 2022-06-30 2024-01-04 Genzyme Corporation Therapeutic tyrosine kinase inhibitors for multiple sclerosis and myasthenia gravis
WO2024081168A1 (en) * 2022-10-11 2024-04-18 Genzyme Corporation Therapeutic tyrosine kinase inhibitors for multiple sclerosis

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2809918A (en) 1955-10-17 1957-10-15 Victor M Hermelin Sustained release pharmaceutical preparations
DE2010416B2 (de) 1970-03-05 1979-03-29 Hoechst Ag, 6000 Frankfurt Oral anwendbare Arzneiform mit Retardwirkung
US3760984A (en) 1971-09-29 1973-09-25 Alza Corp Osmotically powered agent dispensing device with filling means
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US3952741A (en) 1975-01-09 1976-04-27 Bend Research Inc. Controlled release delivery system by an osmotic bursting mechanism
US4728512A (en) 1985-05-06 1988-03-01 American Home Products Corporation Formulations providing three distinct releases
US4794001A (en) 1986-03-04 1988-12-27 American Home Products Corporation Formulations providing three distinct releases
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
EP1451173A4 (en) 2001-11-01 2005-10-26 Icagen Inc PIPERIDINE
US20060045822A1 (en) 2004-09-01 2006-03-02 Board Of Regents, The University Of Texas System Plasma polymerization for encapsulating particles
CA2580343A1 (en) 2004-09-14 2006-03-23 Novartis Vaccines And Diagnostics, Inc. Imidazoquinoline compounds
EP1846405A2 (en) 2005-02-11 2007-10-24 3M Innovative Properties Company Oxime and hydroxylamine substituted imidazo 4,5-c ring compounds and methods
EP2029597A4 (en) 2006-05-31 2011-11-23 Univ California purine analogs
PT2526933E (pt) 2006-09-22 2015-06-23 Pharmacyclics Inc Inibidores da tirosina-quinase de bruton
TW200911803A (en) 2007-07-16 2009-03-16 Organon Nv 6-phenyl-1H-imidazo [4,5-c] pyridine-4-carbonitrile derivatives
UY32138A (es) 2008-09-25 2010-04-30 Boehringer Ingelheim Int Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables
US7718662B1 (en) 2009-10-12 2010-05-18 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
PL2578585T3 (pl) 2010-05-31 2017-01-31 Ono Pharmaceutical Co., Ltd. Pochodna purynonu jako inhibitor kinazy btk
MX2013013331A (es) 2011-05-17 2014-10-17 Principia Biopharma Inc Derivados de azaindol como inhibidores de tirosina-cinasas.
SI2710005T1 (sl) 2011-05-17 2017-03-31 Principia Biopharma Inc. Zaviralci tirozinske kinaze
BR112014012727B1 (pt) 2011-11-29 2022-10-25 Ono Pharmaceutical Co., Ltd Cloridrato de 6-amino-9-[(3r)-1-(2-butinoil)-3-pirrolidinil]-7-(4-fenoxifenil)-7,9-di-hidro-8h-puri- 8-ona e composição farmacêutica
US8501724B1 (en) 2012-01-31 2013-08-06 Pharmacyclics, Inc. Purinone compounds as kinase inhibitors
US20160045503A1 (en) 2012-06-18 2016-02-18 Principia Biopharma Inc. Formulations containing reversible covalent compounds
DK3181567T3 (da) 2012-09-10 2019-06-11 Principia Biopharma Inc Pyrazolopyrimidinforbindelser som kinasehæmmere
BR112015011171A2 (pt) 2012-11-15 2017-07-11 Pharmacyclics Inc compostos de pirrolopirimidina como inibidores da quinase
US20140142099A1 (en) 2012-11-20 2014-05-22 Principia Biopharma Inc. Purinone Derivatives as Tyrosine Kinase Inhibitors
TW201429969A (zh) 2012-12-20 2014-08-01 Merck Sharp & Dohme 作爲ｈｄｍ２抑制劑之經取代咪唑吡啶
HUE036739T2 (hu) 2012-12-21 2018-07-30 Plexxikon Inc Vegyületek és eljárások kináz modulációra, és azok indikációi
AP2016009297A0 (en) 2014-02-03 2016-06-30 Cadila Healthcare Ltd Novel heterocyclic compounds
SG11201701573QA (en) 2014-10-06 2017-03-30 Merck Patent Gmbh Heteroaryl compounds as btk inhibitors and uses thereof
TWI810582B (zh) * 2015-06-03 2023-08-01 美商普林斯匹亞生物製藥公司 酪胺酸激酶抑制劑
CN105753863B (zh) 2015-09-11 2018-07-31 东莞市真兴贝特医药技术有限公司 氧代二氢咪唑并吡啶类化合物及其应用
CA3008653A1 (en) 2015-10-14 2017-04-20 Zibo Biopolar Changsheng Pharmaceutical Co. Ltd. Bruton's tyrosine kinase inhibitors
FI3377484T3 (fi) 2015-11-17 2023-11-30 Merck Patent Gmbh Menetelmiä multippeliskleroosin hoitoon käyttämällä pyrimidiini- ja pyridiiniyhdisteitä, joilla on BTK inhiboiva vaikutus
CN115348862A (zh) 2020-01-20 2022-11-15 建新公司 用于复发型多发性硬化症(rms)的治疗性酪氨酸激酶抑制剂
WO2022081512A1 (en) 2020-10-12 2022-04-21 Synubi Pharmaceuticals Llc Compositions and methods of treatment of neuroinflammatory diseases with bruton's tyrosine kinase inhibitors
AU2021398051A1 (en) 2020-12-10 2023-07-27 Genzyme Corporation Crystal form of tolebrutinib, preparation method therefor and use thereof
EP4328226A1 (en) 2021-04-23 2024-02-28 Hangzhou Solipharma Co., Ltd. Tolebrutinib crystal form, amorphous form, preparation method therefor and use thereof

Also Published As

Publication number Publication date
JP2023510604A (ja) 2023-03-14
EP4093397A1 (en) 2022-11-30
BR112022014058A2 (pt) 2022-09-13
KR20220130179A (ko) 2022-09-26
IL294560A (en) 2022-09-01
US20210244720A1 (en) 2021-08-12
AU2021209608A1 (en) 2022-09-15
TW202140002A (zh) 2021-11-01
US11969418B2 (en) 2024-04-30
WO2021150476A1 (en) 2021-07-29
CA3168146A1 (en) 2021-07-29
CN115348862A (zh) 2022-11-15

Similar Documents

Publication Publication Date Title
MX2022008875A (es) Inhibidores terapeuticos de tirosina quinasa para esclerosis multiple recidivante (emr).
EA202092154A1 (ru) Комбинированная терапия
EA202190630A1 (ru) Способы комбинированной терапии
NZ772688A (en) The use of inhibitors of bruton’s tyrosine kinase (btk)
EA201300246A1 (ru) Ингибиторы тирозинкиназы брутона
GEP20237519B (en) Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer
MX2019003134A (es) Terapia de combinacion.
WO2018208793A8 (en) S-NITROSOGLUTATHIOME INHIBITORS (GSNO) AND GSNO REDUCTASE USEFUL IN THERAPY
MX2020013163A (es) Metodos para tratar trastornos linfoproliferativos malignos.
MX2022001004A (es) Inhibidores de enzimas.
MX2021010058A (es) Formulaciones de rapamicina tópicas y su uso en el tratamiento de angiofibromas faciales y otros trastornos de la piel.
BR112021019070A2 (pt) Ligantes de pseudoquinase tyk2
MX2022016355A (es) Metodos para retardar, prevenir, y tratar la resistencia adquirida a inhibidores de ras.
MX2021006619A (es) Inhibidores de la tirosina quinasa, composiciones y sus metodos.
MX2023009685A (es) Inhibidores de tyk2 y sus usos.
MX2023008968A (es) Inhibidores de cdk2 y metodos de uso de los mismos.
MX2023000187A (es) Dosificacion de vibegron para el tratamiento de vejiga sobreactiva.
BR112021022380A2 (pt) Inibidores de jak
MX2021007948A (es) Inhibidores de proteina de activacion de fibroblastos.
CL2021002878A1 (es) Tratamiento y prevención de enfermedades metabólicas
MX2021009051A (es) Tratamiento de lesiones cutaneas y prurito en pacientes con prurigo nodular.
MX2020011534A (es) Formulacion farmaceutica estable.
MX2023009723A (es) Inhibidores de tyk2 y sus usos.
MX2020009999A (es) Composiciones farmacéuticas para inhibir citocinas inflamatorias.
MX2023014484A (es) Uso de roluperidona para tratar sintomas y trastornos negativos, aumentar la neuroplasticidad y promover la neuroproteccion.